10.10.19

MicroSurgical Technology (MST) Announces the Acquisition of Trabectome and Goniotome

Source: MicroSurgical Technology

In a move to expand its offerings into surgical glaucoma, MST has acquired the assets of NeoMedix Corporation (Tustin, CA) related to glaucoma, including Trabectome and Goniotome product platforms.

Trabectome is an easy to use surgical technology with an clinical history of proven efficacy, according to a company news release. Backed by over 7 years of data, clinical studies show that a significant majority of patients who had Trabectome surgery experienced a sustained IOP reduction to ≤21 mmhg, a 20% improvement from the IOP baseline, and no additional glaucoma surgery.  Another key benefit of Trabectome is significant reduction in glaucoma medication use resulting in simplifying patient compliance. Trabectome uses electrosurgical ablation to assist in easy and complete edge to edge removal of the trabecular meshwork to promote enduring IOP reduction.[1,2]

MST is also introducing Goniotome and Goniotome I/A, two additional innovative solutions for goniotomy. Goniotome offers an easy and effective solution for complete excision of trabecular meshwork. It features serrated blades that are precision engineered using femtosecond laser technology. The trapezoidal configuration enables complete edge to edge removal of diseased trabecular meshwork to provide lasting exposure of collector channels. The Goniotome I/A has an irrigation and aspiration feature that maintains a deep, stable, and clear anterior chamber while improving angle visualization.

Trabectome and Goniotome platforms are indicated for management of pediatric or adult glaucoma such as open or narrow angle glaucoma, primary or secondary glaucoma, and pseudoexfoliative or non-pseudoexfoliative glaucoma. This allows users of the Trabectome and Goniotome to treat more patients and conditions than they could with other MIGS devices.

“Trabectome, Goniotome, and Goniotome I/A are important additions to our innovative and differentiated product solutions portfolio that enable us to better serve our expanding physician customers,” Ramin Mojdeh, President of MST, said in a company news release. “These products provide MST with a solid entry into the MIGS space while we continue to advance our offerings in complex cataract solutions.”

[1] Data on file, 132 peer reviewed studies

[2] Sameh Mosaed: The First Decade of Global Trabectome Outcomes. Clinical & Surgical Ophthalmology, 2014; 32:1

Related Content